
PRESS RELEASE

Ypsomed examines investment options

Burgdorf, 10 July 2012, 6.00 p.m. – At the general meeting of 27 June 2012 Ypsomed shareholders approved the growth strategy: the motion to implement an approved increase in share capital which can be used, among other things, to finance the extension and build-up of international distribution channels and production facilities, was passed by a large majority. Ypsomed is meanwhile in the process of examining various investment options. These also include existing co-operation partners. No talks have been held with potential takeover targets as yet.

The increase in share capital by Ypsomed will only be implemented if specific investment projects are to be carried out, as administrative board chairman and CEO Dr. h. c. Willy Michel explained at the general meeting. The time limit for implementation extends until July 2014.

About the Ypsomed Group

The Ypsomed Group is a leading, independent developer and manufacturer of injection systems for self-medication and a renowned diabetes specialist with over 25 years of experience. Originated in 2003 from the famous company Disetronic, today it offers insulin pumps and injection systems as well as pen needles for the treatment of diabetes, growth disturbances, infertility and other therapeutic areas. Ypsomed is regarded as a leader in innovation and technology and is the preferred partner of pharmaceutical and biotech companies in the self-medication field. Ypsomed has established itself with the umbrella brands mylife™ Diabetescare and YDS™ Ypsomed Delivery Systems in retailing and in business-to-business trading. Under the brand name mylife™ Diabetescare, Ypsomed offers patients an extensive range of self-manufactured products or commercial products for treatment of diabetes. The range from YDS™ reflects the many years of experience and competence in the field of injection systems. With an innovative and patent-protected product line of pen systems and autoinjectors, which can be adapted to customer requirements, contract production in the development and production sectors as well as the assembly of injection systems with medications Ypsomed thus offers demand-orientated product and service solutions to pharmaceutical and biotech companies worldwide.

Ypsomed has its headquarters in Burgdorf. It disposes of several production sites in Switzerland and in the Czech Republic, of subsidiaries throughout Europe as well as leading, independent marketing partners throughout the world. The Ypsomed group has around 1,030 employees.

For further information, please contact Benjamin Overney, head of Investor & Public Relations of Ypsomed Holding AG, on +41 34 424 41 59 (phone) or on +41 34 424 41 55 (fax).